Bronchoscopy: Diagnostic and Therapeutic Airway Procedures — Cost, Top Hospitals & Success Rates | MyMedicPlus

Bronchoscopy is a minimally invasive endoscopic procedure that allows direct visualisation of the tracheobronchial tree from the larynx down to the subsegmental bronchi. It is performed by a pulmonologist or thoracic surgeon and serves as the cornerstone of airway diagnosis and endobronchial therapy. Two principal platforms are used: flexible fibreoptic bronchoscopy (FFB), the standard platform for most diagnostic and therapeutic applications, and rigid bronchoscopy, which provides a large operative channel for haemostasis control, foreign body retrieval, stent placement, and major airway tumour debulking.

The flexible bronchoscope (diameter 5-6mm outer, 2-3mm working channel) is passed transnasally or transorally under conscious sedation with topical anaesthesia. Real-time visualisation of the vocal cords, trachea, carina, and lobar/segmental airways is obtained. Multiple sampling tools can be deployed through the working channel: forceps, brushes, needles, cryoprobes, and balloons. The diagnostic yield depends on lesion location (central vs peripheral), operator experience, and the sampling technique employed.

Modern advanced bronchoscopy has dramatically extended the reach of the flexible scope. EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration) samples mediastinal and hilar lymph nodes with sensitivity exceeding 92%, largely replacing mediastinoscopy for nodal staging. Navigational bronchoscopy systems (electromagnetic, CT-virtual, and robotic platforms including Ion and Monarch) enable access to peripheral pulmonary nodules previously reachable only by CT-guided percutaneous biopsy. Transbronchial cryobiopsy obtains larger, better-quality specimens from the lung parenchyma than conventional forceps biopsy, with significant implications for interstitial lung disease diagnosis.

Pre-procedure preparation includes 4-6 hours of fasting (NPO), coagulation assessment, topical anaesthesia with 2% lignocaine spray and 1% bronchoscopic lavage (maximum dose 8.2 mg/kg ideal body weight), and intravenous sedation with midazolam (1-2 mg) and fentanyl (25-50 mcg), with or without propofol TIVA for deeper sedation.

Bronchoscopy is indicated across a broad range of pulmonary and airway conditions:

• Haemoptysis: Visualisation of the bleeding source; therapeutic control via flexible or rigid bronchoscopy (adrenaline instillation, endobronchial balloon tamponade, argon plasma coagulation, laser photocoagulation).
• Suspected endobronchial malignancy: Direct biopsy of visualised tumour in the central airways; forceps biopsy, brushings, and washings for cytology and histology. Also evaluation of post-obstructive pneumonia or atelectasis.
• Mediastinal and hilar lymphadenopathy: EBUS-TBNA for tissue diagnosis and mediastinal staging of lung cancer (NSCLC) — determines resectability and nodal status (N0-N3) without surgical mediastinoscopy.
• Peripheral pulmonary nodule: Radial EBUS with guide sheath, navigational bronchoscopy, or CT-virtual bronchoscopy for biopsy of lesions beyond the visible bronchoscopic range (>2 cm — yield 60-80%; smaller lesions lower yield).
• Interstitial lung disease (ILD): Bronchoalveolar lavage (BAL) for cell differential (lymphocytic alveolitis in hypersensitivity pneumonitis; neutrophilia in IPF/UIP) and transbronchial cryobiopsy for histological pattern recognition (UIP, NSIP, DIP, RB-ILD).
• Pulmonary infection in immunocompromised hosts: BAL for PCP (Pneumocystis jirovecii), CMV, invasive pulmonary aspergillosis (galactomannan), atypical mycobacteria, bacterial superinfection.
• Foreign body aspiration: Retrieval using flexible forceps (coins, food, teeth) under conscious sedation; rigid bronchoscopy preferred for large objects in children.
• Airway stricture and complications: Tracheal stenosis (post-intubation), post-transplant anastomotic stricture, endobronchial metastases — balloon dilatation and stent placement.

Bronchoscopy is generally safe when performed at an experienced centre with appropriate monitoring. Patient selection and preparation minimise risk:

Standard pre-procedure requirements: NPO 4-6 hours before the procedure. Baseline oxygen saturation, blood pressure, and heart rate monitoring. IV access established. Informed consent obtained covering the specific sampling technique planned.

Anticoagulation management: For bronchoscopic washings and endobronchial forceps biopsy — most anticoagulants can be continued as bleeding risk is low. For transbronchial biopsy (TBB) — INR target <1.5; clopidogrel withheld 5-7 days; NOACs withheld 24-48 hours (depending on renal function). For cryobiopsy — stricter platelet (>100 × 10⁹/L) and coagulation requirements given higher bleeding risk.

Spirometry and lung function: Baseline FEV1 recommended if significant airways disease or bullous emphysema is suspected. FEV1 <1 L is a relative contraindication for TBB (higher pneumothorax risk). Severe pulmonary hypertension (PAP >50 mmHg) increases TBB bleeding risk.

Absolute contraindications: Uncorrectable severe hypoxia refractory to supplemental oxygen; haemodynamic instability or arrhythmia requiring immediate intervention; uncorrectable severe coagulopathy; recent myocardial infarction (<4-6 weeks).

Relative contraindications: Severe asthma (pre-treat with bronchodilators); superior vena cava obstruction; unstable angina; uncooperative patient. Pre-oxygenation via nasal high-flow oxygen or non-rebreather mask maintains SpO₂ >92% during the procedure. Continuous pulse oximetry and ECG monitoring are mandatory.

1. Flexible Fibreoptic Bronchoscopy (FFB) — Diagnostic Sampling:

• Bronchoalveolar Lavage (BAL): 150-200 mL of saline injected in 50 mL aliquots into a sub-segmental bronchus of the affected lobe; fluid aspirated for cell differential, microbiology cultures, cytology (malignant cells), and specialist tests (galactomannan, PCR for organisms). BAL is the primary investigation for ILD and opportunistic infection in immunocompromised patients.
• Endobronchial Forceps Biopsy: Cupped biopsy forceps obtain tissue from visible endobronchial tumour. 3-5 biopsies from different areas of the lesion are recommended for adequate sampling. Sensitivity for visible tumour >85%.
• Bronchial Brushings and Washings: Cytological specimens adjunctive to forceps biopsy; sensitivity lower when used alone but additive when combined with forceps biopsy.
• Transbronchial Lung Biopsy (TBB): Fluoroscopy-guided forceps biopsy of lung parenchyma beyond visible airways. Yield 40-70% for peripheral lesions; improved with 6+ biopsies. Key technique for peripheral nodule sampling in the absence of advanced navigation systems.

2. EBUS-TBNA (Endobronchial Ultrasound-guided Transbronchial Needle Aspiration): A linear-array EBUS scope with a dedicated 22G convex-array needle samples mediastinal and hilar lymph nodes under real-time ultrasound visualisation. Target stations: 2R/2L, 4R/4L, 7 (subcarinal), 10R/10L, 11R/11L. Sensitivity >92% for mediastinal nodal staging — the ASTER trial demonstrated EBUS-TBNA equivalent to mediastinoscopy for N2/N3 staging in NSCLC. ROSE (rapid on-site evaluation) by an on-site cytopathologist confirms specimen adequacy in real time.

3. Radial EBUS with Guide Sheath: A miniature radial probe is advanced beyond the flexible bronchoscope into peripheral bronchi, identifying the target lesion by ultrasound. A guide sheath is left in place after probe removal, through which biopsy forceps or a brush is advanced for sampling. Yield 60-80% for lesions >2 cm; lower for smaller or pure ground-glass lesions.

4. Navigational Bronchoscopy: CT-virtual reconstruction or electromagnetic navigation (ENB) guides the bronchoscope to peripheral lesions. Robotic-assisted platforms (Ion — Intuitive Surgical, Monarch — Auris Health) extend reach further into subsegmental bronchi. The NAVIGATE registry (ENB, n=1,157) reported a 73% diagnostic yield with few complications. Particularly useful for small nodules (<2 cm) where CT-guided biopsy pneumothorax risk is high.

5. Transbronchial Cryobiopsy (TBCB): A liquid nitrogen or CO₂ cryoprobe (1.9-2.4mm) is advanced fluoroscopically to the target area; tissue adherence to the frozen probe yields larger, better-preserved specimens than forceps. COOLBIOPSY and other trials demonstrated superior diagnostic yield for ILD (74-84%) vs conventional TBB (35-55%), approaching surgical lung biopsy (SLB) quality. Higher bleeding risk than forceps (minor bleeding 5-10%; major requiring intervention <2%).

6. Rigid Bronchoscopy — Therapeutic: Performed under general anaesthesia by a thoracic surgeon or interventional pulmonologist. Provides a large (8-12mm) operative channel and allows jet ventilation. Applications: endobronchial tumour debulking (electrocautery snare, APC, cryotherapy, Nd:YAG laser), haemoptysis control (tamponade), stent placement (silicone T-tube or self-expanding metallic stent for malignant/benign airway stenosis), and foreign body retrieval in children.

Bronchoscopy offers diagnostic and therapeutic capabilities that cannot be matched by non-invasive imaging alone:

• Direct airway visualisation: The endoscopic view provides information on mucosal abnormalities (erythema, granularity, submucosal infiltration, exophytic tumour) not detectable by CT scanning.
• Simultaneous diagnosis and staging: EBUS-TBNA obtains pathological tissue from mediastinal nodes while staging nodal involvement in a single session, replacing the two-step approach of CT imaging followed by surgical mediastinoscopy in most patients.
• Avoids more invasive procedures: EBUS-TBNA for mediastinal staging avoids surgical mediastinoscopy (requiring general anaesthesia and a cervical incision) in the majority of patients. Navigational bronchoscopy for peripheral nodules avoids CT-guided biopsy (pneumothorax rate ~25%) in many patients.
• Day-case procedure: Flexible bronchoscopy is performed as a day-case with same-day discharge in most patients who have routine TBB or BAL. Recovery time is 2-4 hours post-procedure.
• Comprehensive microbiological profiling: BAL simultaneously provides specimens for bacterial culture, fungal culture, mycobacteria, viral PCR, and cell differential — enabling diagnosis of multiple possible pathogens in a single procedure.
• Therapeutic capability: Beyond diagnosis, bronchoscopy directly treats haemoptysis, relieves airway obstruction (stent placement, tumour debulking), and retrieves aspirated foreign bodies, avoiding thoracic surgery in many cases.

Flexible bronchoscopy has an excellent safety profile; major complications are uncommon when performed by an experienced operator in a properly equipped setting:

• Minor, procedure-related (common): Transient hypoxia (SpO₂ drop during lavage — managed by oxygen supplementation), cough, mild bronchospasm, transient fever (post-BAL, 5-10%), and minor airway mucosal bleeding from biopsy sites. These are self-limiting and rarely require intervention.
• Bleeding: Minor bleeding at biopsy site occurs in 5-10% of TBB; significant bleeding requiring bronchoscopic intervention (iced saline, adrenaline 1:10,000 instillation, balloon tamponade) in 1-4% of TBB. Risk is higher with cryobiopsy (minor bleeding 5-10%; severe in <2%). Severe haemoptysis requiring rigid bronchoscopy or ICU admission occurs in <0.5% of TBB.
• Pneumothorax: Occurs in 1-5% of patients after TBB (symptomatic in approximately 1%). Post-TBB chest X-ray is obtained routinely. Small pneumothorax (<2 cm apex-to-cupola on PA CXR) — observation only; large or symptomatic — needle aspiration or intercostal drain.
• Laryngospasm or bronchospasm: Rare (<0.5%); managed with oxygen, bronchodilators (nebulised salbutamol), and, if severe, IV suxamethonium for laryngospasm.
• Lignocaine toxicity: Dose-dependent CNS and cardiac toxicity (tinnitus, circumoral numbness, seizures, arrhythmia). Avoided by adhering to maximum dose limits (8.2 mg/kg IBW).
• Cardiovascular events: Transient arrhythmias (benign, usually resolve with oxygen); major cardiorespiratory arrest — extremely rare (0.02-0.04%), predominantly in patients with severe pre-existing cardiopulmonary disease.
• Infection transmission: Risk is negligible with single-use biopsy accessories and high-level disinfection (or ETO sterilisation) of reusable flexible bronchoscopes between patients per ESGE/BTS reprocessing guidelines.

Post-bronchoscopy monitoring and specimen processing are critical components of the procedure pathway:

Immediate post-procedure monitoring: Patients are observed for 2-4 hours in a monitored recovery area. Continuous pulse oximetry, heart rate, and blood pressure monitoring. Patients are allowed to eat and drink once the gag reflex has fully returned (typically 1-2 hours after completion of topical anaesthesia). Chest X-ray is performed after TBB or cryobiopsy to exclude pneumothorax before discharge.

Specimen handling: BAL fluid is sent immediately (at body temperature) for: cell differential count and cytospin; microbiological culture (bacterial, fungal, mycobacterial); viral PCR (CMV, HSV, respiratory viruses); cytology for malignant cells; galactomannan (if invasive aspergillosis suspected). Endobronchial and transbronchial biopsies are placed in 10% neutral buffered formalin for histopathological processing. Additional vials in saline or RPMI medium are retained for flow cytometry (lymphoma workup) or research biobanking.

Results timeline: ROSE provides immediate on-site adequacy assessment within minutes of aspiration. BAL differential and preliminary culture results: 24-48 hours. Tissue histology H&E: 3-5 working days. Immunohistochemistry for ILD pattern or malignancy markers: 5-7 days. EBUS-TBNA cytology from fixed slides: 3-5 days. Cryobiopsy for ILD histological pattern (UIP/NSIP/DIP/RB-ILD): 5-10 days including IHC panel.

Follow-up after diagnostic bronchoscopy: Non-diagnostic results require MDT discussion to determine whether repeat bronchoscopy, CT-guided biopsy, or surgical sampling (VATS lung biopsy) is appropriate. Persistent non-diagnostic results after two bronchoscopic attempts in a patient with high clinical suspicion for malignancy generally warrant CT-guided percutaneous biopsy or VATS resection.

Bronchoscopy costs vary substantially based on the technique employed, imaging and navigation systems used, anaesthesia requirements, and geographic location:

• Standard flexible diagnostic bronchoscopy (BAL + forceps biopsy):
  • India: USD 150-400 all-inclusive (including day-case admission and pathology)
  • Thailand/Malaysia: USD 300-700
  • UAE/Turkey: USD 500-1,200
  • UK (private): USD 1,500-3,000
  • USA: USD 2,000-5,000 (endoscopy suite + pathology billing)
• EBUS-TBNA (mediastinal staging): Adds USD 300-800 in India; USD 1,500-3,000 additional in the USA. Replaces surgical mediastinoscopy (USD 8,000-20,000 in USA) in most patients.
• Navigational bronchoscopy (ENB/robotic): Available at tertiary centres. Adds USD 3,000-10,000 over standard bronchoscopy in high-income settings. Limited availability in India and Thailand; USD 1,000-3,000 at specialist centres where available.
• Cryobiopsy for ILD: Adds USD 400-1,500 depending on probe cost and pathology complexity. Significantly less expensive than surgical lung biopsy (VATS, USD 10,000-30,000).
• Rigid bronchoscopy with stent placement: Requires general anaesthesia; total cost USD 2,000-6,000 in India; USD 10,000-30,000 in USA (including anaesthesia and hardware costs).

Medical tourism for bronchoscopy is meaningful primarily for advanced procedures (EBUS staging, navigational bronchoscopy, stent placement), where cost differentials between India/Thailand and the USA or Australia are 70-85%.

Depending on the clinical indication, the following alternatives to bronchoscopy may be considered:

1. CT-Guided Percutaneous Needle Biopsy: The principal alternative for peripheral pulmonary lesions not accessible by bronchoscopy. Diagnostic yield is higher than standard TBB for peripheral lesions >1 cm (yield 80-95%) but pneumothorax rate is substantially higher (~25%, symptomatic ~5%). Preferred for lesions >1 cm with no bronchus sign on CT (bronchus-to-lesion pathway needed for navigational bronchoscopy to be reliable).

2. Video-Assisted Thoracoscopic Surgery (VATS): Surgical lung biopsy (SLB) by VATS remains the gold standard for ILD diagnosis when cryobiopsy is non-diagnostic or contraindicated. Also used for peripheral nodule resection (wedge excision) when needle biopsy fails or when the nodule has a high pre-test probability of malignancy warranting combined diagnosis and treatment. Major surgery with general anaesthesia required.

3. Mediastinoscopy: Cervical mediastinoscopy under general anaesthesia was historically the gold standard for mediastinal nodal staging. Largely replaced by EBUS-TBNA for most indications. Retained for EBUS-non-accessible stations (anterior mediastinum, stations 5/6) and when EBUS-TBNA is non-diagnostic despite repeat attempt.

4. PET-CT and Liquid Biopsy: PET-CT refines clinical staging and identifies the optimal biopsy target but cannot replace tissue diagnosis. Liquid biopsy (circulating tumour DNA, ctDNA) is validated in NSCLC for EGFR T790M detection at progression, and is increasingly used for molecular profiling when tissue biopsy is insufficient — but is not a replacement for initial diagnosis.